Importantly, the combination therapy of elesclomol and sunitinib profoundly suppressed the proliferation ability of ccRCC cells in a synergistic manner, as demonstrated by the HSA and Bliss synergy scores (786-O: ZIP-score: 17.89, Bliss-score: 17.79; Caki-1: ZIP-score: 11.93, Bliss-score: 11.88; Figures 7J, K). This evidence concerns the gene ALB and nonpapillary renal cell carcinoma.